Omeros Corp (OMER.OQ)
22 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|58||2013||Chairman of the Board, President, Chief Executive Officer|
|58||2013||Chief Accounting Officer, Vice President - Finance, Treasurer|
|57||2007||Vice President - Patent, General Counsel, Secretary|
|77||1995||Lead Independent Director|
- BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721
- BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
- BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
- BRIEF-Omeros Corp reports Q3 loss per share $0.16
- BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721